The Science
Resdevco has established a robust and versatile drug discovery and development platform based on proprietary technologies, broad licenses to fundamental intellectual property and extensive scientific expertise after more than four decades working on influencing the production level of protein in the cell to achieve healing via regulation of gene expression without interfering with genetics.
Our founder
During 50 years of pharmaceutical research, Professor Shabtay Dikstein brought 6 drugs to the international market, based on his exclusive scientific and applied knowledge. In 1980, he became a full professor in applied pharmacology at the Hebrew University and in 2012 was recognized by the university as one of the 24 groundbreaking researchers and inventors of all times.
Professor Dikstein’s research focused on the mechanisms involved in maintaining the healthy function of the cells and in the tissue integrity, particularly with regard to skin and eyes. He has written over 150 scientific papers and was a guest professor at Stanford, London and Oxford Universities. Additionally, he wrote two books and contributed to numerous articles and scientific books.
Professor Dikstein is the founding member of the International Society for Eye Research (ISER), The International Society for Bioengineering and Skin (ISBS), and The International Society for Dacryology (ISD).
The Professor was awarded numerous prizes, among them the first prize of the Hebrew University’s Kaye Innovation Award in 1996, the Ferenc Papolczy Award of the Hungarian Society for Eye Research in 2005 and the Honorary member of Hungarian Ophthalmological Society in 2017.
TREAT INFLAMMATION
VIA mRNA CALIBRATION
Resdevco is a pharmaceutical company that develops and brings to market safe, affordable medications for inflammatory conditions based on the unique Gene Expression Modification platform.
About Us
Resdevco Ltd. is a pharmaceutical research company founded over 40 years ago. Its pioneering work was initiated by Professor Shabtay Dikstein (Professor Emeritus) of the Hebrew University, who is internationally recognized as a visionary inventor and innovator. Resdevco’s strength lies not only in its cutting-edge research platform but also in the robust network of professionals it has cultivated over the past three decades.
Erez Meltzer
EXECUTIVE CHAIRMAN
Dani Shomron
CEO - DIRECTOR R&D
Dr. Liat Lomnitski
DIRECTOR OF SAFETY ASSESSMENT, REGULATORY, TOXICOLOGY,
Prof. Tamas Biro
CHIEF SCIENTIFIC ADVISOR
Dr. G. Bartus
QUALITY DIRECTOR AND FORMULATION
Dr. Susanne Mair
DIRECTOR OF SALES AND MARKET STUDIES
Dr. Richard Schultz
PATENT LAWYER
Current R&D
Since 2021, Resdevco has been dedicated to creating advanced, synergistic formulations that deliver potent tissue healing, anti-inflammatory and anti-irritant moisturizing benefits. Our products are developed with a focus on inherent safety and affordability. New, bio-active, endogenous molecules were added to our arsenal.
Three more new products are being developed in stealth mode.